Shares of Insulet have moved -2.2% today, and are now trading at a price of $170.92. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 938,864 compared to the stock's average volume of 967,564.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Based in Acton, United States the company has 2,600 full time employees and a market cap of $11,933,822,976.
The company is now trading -40.24% away from its average analyst target price of $286.0 per share. The 16 analysts following the stock have set target prices ranging from $208.0 to $360.0, and on average give Insulet a rating of buy.
Over the last 12 months PODD shares have declined by -33.0%, which represents a difference of -49.0% when compared to the S&P 500. The stock's 52 week high is $335.91 per share and its 52 week low is $166.03. Based on Insulet's average net margin growth of 0.9% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
---|---|---|---|---|
2023-02-24 | 1,305,300 | 4,600 | 0 | -100.0 |
2022-02-24 | 1,098,800 | 16,800 | 2 | 100.0 |
2021-02-24 | 904,400 | 6,800 | 1 | -50.0 |
2020-02-26 | 738,200 | 11,600 | 2 | 100.0 |
2019-02-28 | 563,800 | 3,300 | 1 | 116.67 |
2018-02-22 | 463,768 | -26,831 | -6 |